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Abstract
Background: The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for
a favorable prognosis in breast cancer patients. Factors capable of predicting a pCR, such as the proliferation
marker Ki67, may therefore help improve our understanding of the drug response and its effect on the prognosis.
This study investigated the predictive and prognostic value of Ki67 in patients with invasive breast cancer receiving
neoadjuvant treatment for breast cancer.
Methods: Ki67 was stained routinely from core biopsies in 552 patients directly after the fixation and embedding
process. HER2/neu, estrogen and progesterone receptors, and grading were also assessed before treatment. These
data were used to construct univariate and multivariate models for predicting pCR and prognosis. The tumors were
also classified by molecular phenotype to identify subgroups in which predicting pCR and prognosis with Ki67
might be feasible.
Results: Using a cut-off value of > 13% positively stained cancer cells, Ki67 was found to be an independent
predictor for pCR (OR 3.5; 95% CI, 1.4, 10.1) and for overall survival (HR 8.1; 95% CI, 3.3 to 20.4) and distant disease-
free survival (HR 3.2; 95% CI, 1.8 to 5.9). The mean Ki67 value was 50.6 ± 23.4% in patients with pCR. Patients
without a pCR had an average of 26.7 ± 22.9% positively stained cancer cells.
Conclusions: Ki67 has predictive and prognostic value and is a feasible marker for clinical practice. It
independently improved the prediction of treatment response and prognosis in a group of breast cancer patients
receiving neoadjuvant treatment. As mean Ki67 values in patients with a pCR were very high, cut-off values in a
high range above which the prognosis may be better than in patients with lower Ki67 values may be
hypothesized. Larger studies will be needed in order to investigate these findings further.
Background
The aim in modern, individualized medicine is to iden-
tify patients who have an unfavorable prognosis – or
even better, to identify patients who may be capable of
benefiting from an improved prognosis associated with a
specific form of treatment. There has recently been dis-
cussion on whether the proliferation marker Ki67 might
be suitable for inclusion in everyday clinical practice,
although it was considered that the marker is not yet
ready for routine use [1]. In novel multigene tests, how-
ever, proliferation has a major impact on calculations of
the risk of recurrence. Ki67 itself is already part of a
multigene test [2] that is being used in clinical studies
such as the TailorX and the planB studies [3]. In a
study including a group of women receiving antihormo-
nal treatment, it has been suggested that using Ki67,
estrogen receptor (ER), progesterone receptor (PR), and
the HER2/neu receptor (HER2) may have a prognostic
value similar to that of a multigene prognostic score [4].
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has been demonstrated both in patients undergoing che-
motherapy and in patients treated with antihormonal
therapy [5], and some of its effect on the outcome
appears to be unrelated to any specific form of therapy.
It might therefore be reasonable to assume that the cor-
relation of Ki67 with breast cancer outcome involves a
mixture of prognostic and predictive effects.
The neoadjuvant setting is a useful model for investi-
gating the value of Ki67 as a predictive and prognostic
factor. Some neoadjuvant studies have investigated Ki67
in relation to complete pathological response (pCR), and
one has examined its association with disease progres-
sion during neoadjuvant therapy [6]. The majority of
studies investigating pCR have identified a high Ki67
proliferation rate as a predictive factor for a higher rate
of pCR (reviewed in [5]), but the only study that has
examined progression during neoadjuvant chemotherapy
found that patients in whom progression occurred had a
higher proliferation rate than those who responded to
chemotherapy [6]. This suggests a nonlinear effect of
Ki67 on the treatment response and possibly the
prognosis.
As a variety of studies have now established that pCR
is a surrogate marker for prognosis [7-9], a cohort cap-
able of providing pretreatment predictive markers, infor-
mation on pCR, and follow-up data might be able to
identify patients who still have a favorable prognosis
despite a lack of complete response to neoadjuvant ther-
apy – while vice versa, it might also help identify
patients who still have a poorer prognosis even after a
pCR.
The aim of the present study was therefore to investi-
gate Ki67 immunohistochemistry with regard to its abil-
ity to predict treatment response in a group of
neoadjuvantly treated breast cancer patients and to cor-
relate Ki67 expression with prognosis within the differ-
ent response groups to chemotherapy.
Methods
Patients
The patients included in this retrospective study were
selected from all patients with invasive breast cancer
treated with neoadjuvant chemotherapy at the Univer-
sity Breast Center for Franconia (Bavaria, Germany)
between January 2002 and December 2008. For inclu-
sion in the study, the patients had to be at least 18 years
of age and had to have undergone surgery following the
neoadjuvant chemotherapy. Information on the follow-
ing parameters had to be available from the pretreat-
ment assessment: patient’sa g e ,t u m o rs i z e ,e s t r o g e n
receptor status, progesterone status, HER2 status, grad-
ing, and proliferation status as assessed by Ki67 staining.
The patient selection process is shown in Figure 1.
Approval for the analyses conducted in the study was
received from the ethics committee of the medical
faculty at the University of Erlangen-Nuremberg.
Informed consent was obtained from patients whose
data have been included in this study.
Clinical data
The University Breast Center for Franconia has received
certification from the German Cancer Society and the
German Society for the Study of Breast Diseases
(Deutsche Gesellschaft für Senologie). To obtain certifica-
tion, a breast center has to document each case of breast
cancer, including patient and tumor characteristics, treat-
ment data, and some epidemiological data (http://www.
onkozert.de). As part of the certification process, it is
checked whether treatment decisions for patients are in
accordance with the German guidelines for the treatment
of breast cancer. Follow-up information regarding local
recurrences, distant metastases, and death has to be pro-
vided for up to 10 years after the initial diagnosis. All his-
topathological data also have to be documented from the
original pathological reports, including tumor size, axil-
lary lymph-node status, grading, and estrogen receptor,
progesterone receptor, and HER2/neu status. Breast cen-
ters and their data quality are audited annually as part of
the continuous certification process. Data obtained
through these processes were used in the analysis pre-
sented here. A complete pathological response was
defined as no evidence of any tumor cells in the breast
and no evidence of any tumor cells in the axilla.
Figure 1 Patient selection.
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All of the histopathological information used in the analy-
sis was directly documented from the original pathology
reports, which were reviewed by two investigators. Grad-
ing, tumor type, estrogen receptor status, progesterone
receptor status, HER2/neu status, and proliferation status
as assessed by Ki67 staining have been routinely recorded
at the breast center since 1995 and performed on forma-
lin-fixed, paraffin-embedded tumor tissue. Monoclonal
mouse antibodies against estrogen receptor-alpha (clone
1D5; 1: 200 dilution, DAKO, Denmark), monoclonal
mouse antibody against the progesterone receptor (clone
pgR636, 1: 200 dilution, DAKO, Denmark), and monoclo-
nal antibody against Ki67 (clone MIB-1, 1: 200 dilution,
DAKO, Denmark) were used to stain the pretreatment
core biopsies. The percentage of positively stained cells
was included in the pathology reports. The tumors were
considered to be positive for the estrogen and progester-
one receptors if 10% or more of the cells showed positive
staining. The cut-off point for Ki67 status was regarded as
more than 13% positively stained cells, in accordance with
the biological analysis presented by Cheang et al. [10].
This cut-off was chosen because it lies in the range
reported in published studies [5] and also has a correlate
with molecular subtypes of breast cancer [10]. A polyclo-
nal antibody against HER2/neu (1: 200 dilution, DAKO,
Denmark) was used, and HER2 status was given in the
pathology reports as negative, 0, 1+, 2+, or 3+ in accor-
dance with the guidelines published by Sauter et al. [11].
Tumors with a score of 0 or 1+ were regarded as HER2-
negative and those with a score of 3+ were regarded as
HER2-positive. Tumors with a 2+ staining were tested for
gene copy numbers of Her2 by chromogene in-situ hybri-
dization. Using a kit with two probes of different colors
(ZytoDot, 2C SPEC HER2/CEN17, Zyto Vision Ltd., Bre-
merhaven, Germany), the gene copy numbers of HER2
and centromeres of the corresponding chromosome 17
were retrieved. A HER2/CEN17 ratio of ≥ 2.2 was consid-
ered as amplification of HER2.
Scoring was carried out in a standardized way by a
group of dedicated pathologists in routine surgical
pathology. With regard to Ki67, areas with the highest
Ki67 labeling were investigated and approximately 500
cells were counted with 400-fold magnification.
The pCR assessment was based on histopathological
reports, all from one institution. Patients with an ypT0
ypN0 assessment were considered to have achieved a
pathological complete response (pCR). No invasive or
noninvasive residual tissue in the breast or nodes was
allowed, as in Sinn’s assessment [12].
Statistical considerations
The characteristics of patients with pCRs and patients
without pCRs were compared using the appropriate
unpaired statistical tests. Welch’s t-tests were used for
continuous characteristics, chi-squared tests with conti-
nuity correction for categorical characteristics, and the
Armitage trend test for ordinal categorical characteristics.
For each risk parameter, the odds ratio (OR) for pCR
versus no pCR was calculated using simple logistic
regression models. To study the additional predictive
value of Ki67 relative to pCR, a multiple logistic regres-
sion model including all risk factors except for Ki67 was
fitted. Backward stepwise variable selection was carried
out to obtain the best model in accordance with the
Akaike information criterion (the final model). The risk
factor of Ki67 was then added to the final model (pro-
viding the extended final model) and the two models
were compared both with the likelihood ratio test and
with its receiver operating characteristic (ROC) curves.
In addition, the predictive power of the extended final
model was measured using the area under the curve
(AUC) and the sensitivity and specificity of the optimal
cut-off point were assessed in accordance with Youden’s
index. To take overfitting into account, these predictive
measures were evaluated using 20-fold cross-validation
and with the 0.632+ bootstrapping method with 500
bootstrap samples [13,14].
Overall survival, distant disease-free survival, and local
recurrence-free survival were the outcomes of interest in
the prognosis analyses. Survival rates were estimated
using the Kaplan-Meier product limit method. Differ-
ences between survival curves were tested using the log-
rank test. Multiple Cox proportional hazard (PH)
models were used to obtain hazard ratios (HRs). For
each outcome, a full model containing all risk factors
except for pCR was constructed, and the final model
was again contained using backward stepwise variable
selection. The extended final model with the remaining
risk factors and also pCR was fitted. The final model
and the extended final model were compared using the
likelihood ratio test to assess the prognostic value of
pCR. The proportional hazard assumptions were
checked using tests that correlate scaled Schoenfeld resi-
duals with a suitable time transformation [15].
An optimal cut-off point for Ki67 was calculated with
respect to pCR status, using the minimum P value
approach. Within the 10th and 90th percentiles of Ki67,
all values for this variable are considered as potential
cut-off points. The optimal cut-off point is then taken
in such a way that the P value of the simple logistic
regression model, with pCR as the target variable and
Ki67 categories (below and above the cut-off point,
respectively) as predictor variables, is a minimum.
All of the tests were two-sided, and a P value < 0.05
was regarded as statistically significant. Calculations
were carried out using the R system for statistical com-
puting (version 2.11.1; R Development Core Team,
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were used for bootstrapping.
Results
Patient characteristics
A total of 552 patients (mean age 53.3 ± 11.8 years)
were included in the study. Their mean body mass
index (BMI) was 26.1 ± 5.1. Before the chemotherapy
treatment, most of the patients had cT2 tumors 2-5 cm
in size (67.5%) and cT1 tumors up to 2 cm in size
(16.7%). A relevant proportion of the patients had cT4
cancers (11.1%). With regard to the other characteristics,
ductal tumors (80.8%) and a grading of 1 or 2 (65.7%)
were the most commonly observed categories. With a
cut-off value of > 13% positively stained tumor cells for
Ki67, most of the tumors (70.7%) were classified as hav-
ing a high level of Ki67 proliferation. The patients’
characteristics are summarized in Table 1. The median
follow-up time was 2.8 years, with 68 deaths, 78 distant
metastases, and 31 local recurrences.
With regard to the treatments administered, 122
patients (22%) received an anthracycline-based regimen
without taxanes; 328 (60%) were treated with anthracy-
clines and taxanes; and 102 (18%) underwent other
treatments (taxane only; anthracycline only; and cyclo-
phosphamide, methotrexate, or fluorouracil only). Fifty
of the 103 HER2-positive patients (49%) were treated
with trastuzumab in a combined therapy together with
an anthracycline- and taxane-based regimen. Among the
52 patients who did not receive neoadjuvant trastuzu-
mab treatment, 25 (48%) received trastuzumab as an
adjuvant treatment. The rest of the HER2-positive
patients did not receive trastuzumab. There were no
associations between the choice of therapy and the most
Table 1 Pretreatment patient characteristics and univariate associations with pathological complete remission
All pCR no pCR yes
Mean or n SD or % Mean or n SD or % Mean or n SD or % P
Age 53.3 11.8 54.2 11.5 50.0 12.3 < 0.01
BMI 26.1 5.1 26.4 5.3 25.1 4.1 < 0.01
cT
1 92 16.7 60 65.2 32 34.8 < 0.0001
2 372 67.5 292 78.5 80 21.5
3 26 4.7 24 92.3 2 7.7
4 61 11.1 56 91.8 5 8.2
Grading
1 28 5.6 26 92.9 2 7.1 < 0.00001
2 301 60.1 269 89.4 32 10.6
3 172 34.3 94 54.7 78 45.3
Histology
Ductal 445 80.8 338 76.0 107 24.0 0.001
Lobular 80 14.5 76 95.0 4 5.0
Other 26 4.7 18 69.2 8 30.8
ER Status
Negative 198 35.9 103 52.0 95 48.0 < 0.00001
Positive 354 64.1 329 92.9 25 7.1
PR Status
Negative 259 46.9 157 60.6 102 39.4 < 0.00001
Positive 293 53.1 275 93.9 18 6.1
HER2 Status
Negative 445 81.4 366 82.2 79 17.8 < 0.00001
Positive 102 18.6 61 59.8 41 40.2
Ki67
Low 162 29.3 155 95.7 7 4.3 < 0.00001
High 390 70.7 277 71.0 113 29.0
Postoperative radiation
No 63 15.9 47 74.6 16 25.4 0.94
Yes 333 84.1 255 74.2 86 25.8
BMI, body mass index; cT, clinical tumor stage (TNM classification); Ki67, proliferation status, with an immunohistological staining cut-off value of > 13%; pCR,
pathological complete remission; ER, estrogen receptor; PR, progesterone receptor.
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cycline treatment (P = 0.41) or taxane treatment (P =
0.37) in the total group of patients or with regard to
trastuzumab treatment (P =0 . 7 1 )i nt h eg r o u po f
HER2-positive patients.
Univariate analysis for the association with pCR
Complete remissions – i.e., no tumor cells found in the
breast and no tumor cells found in the axilla – were
observed in 120 of the 552 patients (21.7%). The com-
mon prognostic factors in these patients showed
expected associations with pCR. Patients with a pCR
were more likely to be younger (50.0 vs. 54.2 y) and
were more likely to have a lower BMI (25.1 vs. 26.4 kg/
m
2). Small tumors were associated with a higher pCR
rate, as were tumors that were higher-grade, non-lobu-
lar, hormone receptor-negative, and HER2-positive.
Using a cut off value of > 13% positively stained can-
cer cells, pCRs were observed in 113 of 390 patients
(29%) with a high proliferative status as assessed by
Ki67 and in seven of 162 patients (4.3%) with a low pro-
liferative status (Table 1).
Multivariate analysis for predicting pCR
As Ki67 was strongly associated with pCR in the univariate
analysis, two multivariate models were constructed in
order to investigate the incremental benefit of including
Ki67 in a multivariate prediction model for pCR. The first
model did not take Ki67 into account as a predictive fac-
tor. In this model, cT, grading, ER, PR, and HER2 status
were independent predictive factors for complete patholo-
gical remission (Table 2).
The second model included Ki67 in the logistic regres-
sion model. All of the parameters included in the first
model continued to be significant predictive factors for
pCR. In addition, Ki67 also proved to be an independent
predictive factor for pCR, with an odds ratio of 3.51 (95%
CI, 1.41 to 10.1; P = 0.01, Table 3). Using this model, the
bootstrap-validated sensitivity and specificity rates were
82% and 75%, respectively. Using 20-fold cross-validation,
these values represented 82% and 74%, respectively.
Comparison of the two prediction models
When the models were compared with each other using
receiver operating characteristics, including Ki67 in the
prediction model showed an improvement with regard
to the area under the curve, although the benefit
appeared to be marginal. The bootstrap-estimated AUC
values were 0.83 without Ki67 and 0.84 with Ki67. The
benefit appeared to be marginal because Ki67 status and
pCR status are unbalanced (e.g., only seven patients
with Ki67 low and without pCR) in such a way that the
majority of the patients cannot be better classified by
the extended model. The difference between the two
models with regard to the likelihood ratio test was sta-
tistically significant (P < 0.01), although significance did
not persist after bootstrap validation.
Pathological remission rates in molecular subtypes
Table 4 shows the pCR rates for each category (triple-
negative tumors, ER/PR-positive tumors, HER2-negative
Table 2 Prediction of pathological complete remission
without Ki67, using multiple linear regression analysis
(final model)
Characteristic OR 95% CI P
pT
11 - -
2-4 0.39 0.21-0.73 < 0.01
Grading
1-2 1 - -
3 2.95 1.67-5.24 < 0.001
Estrogen receptor status
Negative 1 - -
Positive 0.28 0.13-0.57 < 0.001
Progesterone receptor status
Negative 1 - -
Positive 0.42 0.19-0.92 0.03
HER2/neu receptor status
Negative 1 - -
Positive 2.42 1.36-4.32 < 0.01
CI, confidence intervals; OR, odds ratio; pT, pathological tumor stage (TNM
classification).
Table 3 Prediction of pathological complete remission
with Ki67, using multiple linear regression analysis
(extended final model)
Characteristic OR 95% CI P
pT
11 - -
2-4 0.34 0.18-0.65 < 0.01
Grading
1-2 1 - -
3 2.51 1.41-4.49 < 0.01
Estrogen receptor status
Negative 1 - -
Positive 0.30 0.14-0.63 < 0.01
Progesterone receptor status
Negative 1 - -
Positive 0.50 0.22-1.14 0.10
HER2/neu receptor status
Negative 1 - -
Positive 2.37 1.33-4.22 < 0.01
Ki67
Low 1 - -
High 3.51 1.41-10.10 0.01
CI, confidence intervals; OR, odds ratio; pT, pathological tumor stage (TNM
classification).
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cal value of Ki67 in absolute figures. There was a differ-
ence between tumors with high Ki67 proliferation and
those with low proliferation for each molecular tumor
subtype, but no statistical significance was found for tri-
ple negatives, as the number of triple-negative tumors
with low proliferation was very small (seven of 122).
Hormone receptor-positive tumors were associated with
the lowest rates of pCR. Tumors that were ER-positive
with a low Ki67 proliferation rate were associated with
pCRs in 2.9% of cases, and tumors with a high Ki67
proliferation rate were associated with pCRs in 8.0% of
cases (P = 0.03). One of the seven patients (14.3%) with
triple-negative tumors with a low proliferation rate had
a pCR; 60 of 122 patients with triple-negative tumors
with high proliferation rates had pCRs (49.2%).
Approximately half of the HER2-positive patients
received anti-HER2 treatment with trastuzumab in the
neoadjuvant setting (n = 50), and 52% of these patients
(n = 26) had pCRs. Patients who did not receive neoad-
juvant trastuzumab only had pCRs in 29% of cases (n =
15). With regard to Ki67, the sample sizes were too
small for comparison between the treated and untreated
groups. When the two treatment groups were taken
together, Ki67 was capable of distinguishing the HER2-
positive group into one with a 14.3% pCR rate and one
with a 44.3% pCR rate (P = 0.03) (Table 4).
Empirical cut-off calculations
To improve the predictive value of Ki67 in each molecu-
lar subgroup, P values and pCR rates were calculated for
each possible Ki67 value (Figure 2, 3, 4). In the triple-
negative subgroup, this cut-off was between 30% and
40% positively stained cells. The corresponding odds
ratio for this value was 5.9 (95% CI, 1.9 to 18.6; P =
0.002). With regard to the hormone receptor-positive,
HER2-negative group, this Ki67 value was between 36%
and 40% positively stained cells, with an OR of 7.4 (95%
CI, 2.8 to 19.8; P < 0.0001). In the HER2-positive group,
Ki67 as a predictive factor had the lowest P values at
between 17% and 20% positively stained cells, with an
OR of 3.9 (95% CI, 1.2 to 12.5; P = 0.02). None of these
cut-off values were validated. For comparison of the
effect of these cut-off values with a cut-off value of 13%,
the respective pCR rates with these subgroup specific
cut-off values are shown in Table 5.
Prognostic analysis of the cohort
As Ki67 did have an effect on the pCR, the additional
value of pCR was tested with regard to the prognosis
with multivariate Cox proportional hazard (PH) models
for each of the outcome parameters – overall survival
(OS), distant disease-free survival (DDFS), and local
recurrence-free survival (LRFS) – firstly without the
parameter of pCR, and then including it (Tables 6 and
7).
When pCR was not included, only PR positivity and
Ki67 had prognostic value for OS and DDFS. The clini-
cal tumor stage (cT) also had prognostic value relative
to DDFS. None of the parameters showed clear statisti-
cal significance relative to LRFS (Table 6). When pCR
was included, Ki67 maintained a statistically significant
prognostic value for OS and DDFS, but not for LRFS
(Table 7). Including pCR improved the prognostic value
of the model, with differences in the chi-squared value
(likelihood ratio test) of 21.2 for OS and 23.8 for DDFS
(both P < 0.00001). Bootstrap validation reduced these
values only slightly (data not shown).
To display these effects, Kaplan-Meier curves were
constructed for the following groups of patients: those
with triple-negative tumors, with and without pCR;
those with HER2-positive tumors, with and without
pCR; and those with ER/PR-positive and HER2-negative
tumors, with and without pCR (Figure 5, 6, 7). Patients
in the pCR groups had better outcomes than the corre-
sponding patients without pCRs. This effect was
Table 4 Pathological complete response relative to molecular subtypes of tumor
Tumor classification (+: yes/-: no) Tumor response
ER/PR HER2 Ki67 Neoadjuvant All pCR no pCR yes
trastuzumab N % n % n % P
Hormone receptor-positive + - + NA 176 100 162 92.0 14 8.0 0.05
+ - - NA 140 100 136 97.1 4 2.9
+ or - + + + or - 88 100 49 55.7 39 44.3 0.03
+ or - + - + or - 14 100 12 85.7 2 14.3
HER2-positive + or - + + or - + 50 100 24 48.0 26 52.0 0.03
+ or - + + or - - 52 100 37 71.2 15 28.8
Triple negative - - + NA 122 100 62 50.8 60 49.2 0.12
- - - NA 7 100 6 85.7 1 14.3
All + or - + or - + or - + or - 547 100 427 78.1 120 21.9
ER, estrogen receptor; HER2, HER2/neu receptor; NA, not applicable; PR, progesterone receptor.
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triple-negative tumors and those with ER/PR-positive
tumors, and also relative to OS for patients with triple-
negative tumors and HER2-positive tumors.
An analysis of the prognosis in different molecular
subgroups, different Ki67 groups, and different pCR
behaviors did not seem reasonable due to very small
sample sizes in some of the groups. Mean and median
Figure 2 Cut-off calculations for predicting a pathological complete response (pCR) in the group of triple-negative patients.T h e
continuous line represents the -lg of the P value for each respective cut-off point relative to the percentage of Ki67-positive stained tumor cells.
The dashed line represents the proportion of patients with a pCR in the group of patients with the higher Ki67 values for each cut-off. The gray
background indicates the area for which cut-offs with a significance level of 0.05 is reached. For the maximum of each -lg (P value), the sample
size and pCR rates are provided in the figure.
Figure 3 Cut-off calculations for predicting a pathological complete response (pCR) in the group of ER/PR-positive and HER2-negative
patients. The continuous line represents the -lg of the P value for each respective cut-off point relative to the percentage of Ki67-positive
stained tumor cells. The dashed line represents the proportion of patients with a pCR in the group of patients with the higher Ki67 values for
each cut-off. The gray background indicates the area for which cut-offs with a significance level of 0.05 is reached. For the maximum of each -lg
(P value), the sample size and pCR rates are provided in the figure.
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groups of Kaplan-Meier estimates from the continuous
Ki67 variable, to give an impression of the Ki67 value
for each of the Kaplan-Meier curves. Box plots, means,
and P values for these values are shown in Figure 8.
Discussion
This retrospective study investigated the value of Ki67
as a predictive factor in relation to neoadjuvant
chemotherapy and possible effects on prognosis. Ki67
was found to be an independent predictor for pathologi-
cal complete responses and for the prognosis in all
patients across all subtypes. Looking at Ki67 values in
different molecular subtypes, it seemed that patients
with triple-negative or hormone receptor-positive, HER2-
negative breast cancer had a more favorable prognosis
when a pCR was achieved, although these patient groups
had a higher Ki67 proliferation rate. These results might
Figure 4 Cut-off calculations for predicting a pathological complete response (pCR) in the group of HER2-positive patients.T h e
continuous line represents the -lg of the P value for each respective cut-off point relative to the percentage of Ki67-positive stained tumor cells.
The dashed line represents the proportion of patients with a pCR in the group of patients with the higher Ki67 values for each cut-off. The gray
background indicates the area for which cut-offs with a significance level of 0.05 is reached. For the maximum of each -lg (P value), the sample
size and pCR rates are provided in the figure.
Table 6 Cox proportional hazard ratios without pCR variable for overall survival, distant disease-free survival, and
local recurrence-free survival (three unique models)
Outcome Characteristic HR 95% CI P
OS PR Negative 1 - -
Positive 0.62 0.39-0.99 0.05
Ki67 Low 1 - -
High 7.07 2.82-17.75 < 0.0001
DDFS cT 1 1 - -
2-4 2.69 0.98-7.37 0.05
PR Negative 1 - -
Positive 0.64 0.41-0.99 0.05
Ki67 Low 1 - -
High 2.72 1.49-5.00 < 0.01
LRFS PR Negative 1 - -
Positive 0.49 0.24-1.02 0.06
Ki67 Low 1 - -
High 1.76 0.74-4.21 0.21
CI, confidence intervals; cT, clinical tumor stage (TNM classification); DDFS, distant disease-free survival; HR, hazard ratio; LRFS, local recurrence-free survival; OS,
overall survival; PR, progesterone receptor.
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going chemotherapy may need to be set at a higher level
in these subgroups to allow prediction of the che-
motherapy response with a translation to the prognosis.
In the present study, the pCR rate in patients with
triple-negative tumors (47.3%) was in the range
reported in previously published studies (22-58%)
[8,16-19]. The pCR rates in HER2-positive carcinomas
(28% without and 52% with neoadjuvant trastuzumab
treatment) were higher than in the NOAH study (19%
and 38%) [20], GeparQuattro study (31.7% for patients
t r e a t e dw i t ht r a s t u z u m a b )[ 2 1 ] ,a n dT E C H N Os t u d y
(42% for patients treated with trastuzumab) [22], but
t h es a m p l es i z e si nt h ep r e s e n ts t u d yw e r em u c h
Figure 5 Kaplan-Meier curves with 5 year survival rate estimates (OS) and respective 95% confidence intervals (CI) for overall survival
according to pathological complete responses (pCRs). ER, estrogen receptor; HER2, HER2/neu receptor; PR, progesterone receptor.
Table 5 Pathological complete response relative to molecular subtypes of tumor with empirical cut-offs for Ki67
Tumor classification (+: yes/-: no) Tumor response
ER/PR HER2 Ki67 Neoadjuvant All pCR no pCR yes
trastuzumab N % n % n % P
Hormone receptor-positive + - ≥ 38% NA 53 100 43 81.1 10 18.9 < 0.0001
+ - < 38% NA 263 100 255 97.0 8 3.0
+o r- + ≥ 18% + or - 80 100 43 53.7 37 46.3 0.02
HER2-positive + or - + < 18% + or - 22 100 18 81.8 4 18.2
+ or - + + or - + 50 100 24 48.0 26 52.0 0.03
+ or - + + or - - 52 100 37 71.2 15 28.8
Triple negative - - ≥ 35% NA 105 100 48 45.7 57 54.3 < 0.01
- - < 35% NA 24 100 20 83.3 4 16.7
All + or - + or - + or - + or - 547 100 427 78.1 120 21.9
ER, estrogen receptor; HER2, HER2/neu receptor; NA, not applicable; PR, progesterone receptor.
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Page 9 of 13smaller. The pCR rate in the HER2-negative, hormone
receptor-positive group (5.7%) was also consistent with
that in other published studies [23]. The present study
also confirms previous reports that pCR is associated
with a more favorable prognosis in some molecular
subgroups [8,24].
Previously published parameters such as age, BMI,
tumor stage, histological type, hormone receptor and
HER2 status correlated with pCR, as in other previously
published studies [23,25]. Ki67 also had a strong correla-
tion with pCR and added independently to the predic-
tive value of a logistic regression model. This effect was
present with regard to the total group of patients and
with regard to the molecular subtypes of breast cancer
as defined by hormone receptor and HER2 status. It
reached statistical significance in the hormone and
HER2 receptor-positive groups, with a cut-off at 13%,
but not with regard to the triple negative group. Cut-off
calculations within the molecular subgroups showed
that much better differentiation between treatment
response groups could be achieved with much higher
Ki67 cut-off values for the hormone receptor-positive
group (between 36% and 40%) and the triple-negative
group (between 30% and 40%). For the HER2-positive
group, the cut-off value was between 17% and 20%.
However, this group is difficult to interpret, as it
included patients with and without neoadjuvant trastu-
zumab treatment.
Triple-negative tumors generally have a much higher
proportion of Ki67-positive cells, and differentiation
between responsiveness groups could thus be expected
at a higher level. However, in the hormone receptor-
positive group, previous molecular analysis determined
a cut-off at 13% to differentiate between luminal A
Table 7 Cox proportional hazard ratios including the pCR
variable for overall survival, distant disease-free survival,
and local recurrence-free survival (three unique models)
Outcome Characteristic HR 95% CI P
OS PR Negative 1 - -
Positive 0.47 0.29-0.75 < 0.01
Ki67 Low 1 - -
High 8.14 3.25-20.35 < 0.0001
pCR No 1 - -
Yes 0.18 0.07-0.45 < 0.001
DDFS cT 1 1 - -
2-4 2.42 0.88-6.59 0.08
PR Negative 1 - -
Positive 0.49 0.32-0.76 < 0.01
Ki67 Low 1 - -
High 3.24 1.77-5.89 < 0.001
pCR No 1 - -
Yes 0.16 0.07-0.43 < 0.001
LRFS PR Negative 1 - -
Positive 0.47 0.22-1.00 0.05
Ki67 Low 1 - -
High 1.81 0.75-4.36 0.18
pCR No 1 - -
Yes 0.83 0.34-2.02 0.69
Figure 6 Kaplan-Meier curves with 5 year survival rate estimates (OS) and respective 95% confidence intervals (CI) for distant disease-
free survival according to pathological complete responses (pCRs). ER, estrogen receptor; HER2, HER2/neu receptor; PR, progesterone
receptor.
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Page 10 of 13and luminal B tumors [10]. This cut-off does not
appear to be the best for predicting the chemotherapy
response.
Patients with tumors that have a very high level of pro-
liferation might possibly have a better prognosis than
those with lower Ki67 values as a result of a successful
therapy response. In the present study, this was shown
indirectly for the triple-negative and hormone receptor–
positive subgroup. Patients with a pCR had a better prog-
nosis and a higher mean Ki67 value, whereas patients
with a lower Ki67 value had a more unfavorable prog-
nosis. This might explain some of the inconsistencies in
reports concerning the prognostic value of Ki67 [5].
One aspect of the present study involves both advan-
tages and disadvantages. On the one hand, the methods of
Ki67 staining and evaluation used are part of routine clini-
cal practice. The staining and assessment of whole sections
may be a strength, as most published studies use tissue
microarrays and are unable to account for heterogeneously
expressed Ki67 in a whole slide section. In addition, the
fixation and staining procedures were carried out directly
after the fixation and embedding of the core biopsies into
paraffin. This may have reduced the potential for variabil-
ity in studies using paraffin blocks of different ages, ran-
ging up to decades. On the other hand, routine clinical
assessment means that different batches of chemicals and
antibodies are used, and also that there are different obser-
vers involved. Another problematic issue might concern
the arbitrary molecular classification of tumors used [26].
Approximately 30% of luminal B tumors are HER2-posi-
tive [27]. Patients with these tumors were included in the
HER2-positive group in the present study. However,
further subcategorization was not possible due to the
small sample sizes in the subgroups, and not all of the
HER2-positive patients were treated with trastuzumab.
It would have been desirable to validate other cut-off
values for Ki67 in a sample set of patients treated with
chemotherapy, but the sample size in the present study
appeared to be too small to pursue this aim.
Conclusions
Ki67 provides additional and independent predictive
information regarding the response to chemotherapy
and the prognosis in a group of patients receiving
neoadjuvant treatment for breast cancer. It would be
easy to include it in the panel of markers routinely
assessed in clinical practice. The findings of the present
study suggest that this marker could help select patients
who are unable to benefit from chemotherapy, such as
those with HER2-negative and hormone receptor-
Figure 7 Kaplan-Meier curves with 5 year survival rate estimates (OS) and respective 95% confidence intervals (CI) for local
recurrence-free survival according to pathological complete responses (pCRs). ER, estrogen receptor; HER2, HER2/neu receptor; PR,
progesterone receptor.
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Page 11 of 13positive tumors with low proliferation. On the other
hand, however, it is more difficult to identify patients
who are definitely capable of benefiting from che-
motherapy with a response, and it is also difficult to
translate response results into a general prognosis.
Further research is needed in groups of patients under-
going chemotherapy that are large enough for these
issues to be addressed in relation to the distinct molecu-
lar subtypes of breast cancer and in which two cut-off
values for the prognosis can be taken into account.
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